J Liver Cancer.  2024 Mar;24(1):23-32. 10.17998/jlc.2024.02.21.

Intermediate-stage hepatocellular carcinoma: refining substaging or shifting paradigm?

• Stefanini B
• Ielasi L
• Pallotta DP
• Penazza S
• Marseglia M
• Piscaglia F

• KMID: 2553815
• DOI: http://doi.org/10.17998/jlc.2024.02.21

Abstract

This review explores the evolution of cancer staging, focusing on intermediate hepatocellular carcinoma (HCC), and the challenges faced by physicians. The Barcelona Clinic Liver Cancer (BCLC) staging system, introduced in 1999, was designed to address the limitations associated with providing accurate prognostic information for HCC and allocating specific treatments, to avoid overtreatment. However, criticism has emerged, particularly regarding the intermediate stage of HCC (BCLC-B) and its heterogeneous patient population. To overcome this limitation, various subclassification systems, such as the Bolondi and Kinki criteria, have been proposed. These systems are aimed at refining categorizations within the intermediate stage and have demonstrated varying degrees of success in predicting outcomes through external validation. This study discusses the shift in treatment paradigms, emphasizing the need for a more personalized approach rather than strictly adhering to cancer stages, without dismissing the relevance of staging systems. It assesses the available treatment options for intermediate-stage HCC, highlighting the importance of considering surgical and nonsurgical options alongside transarterial chemoembolization for optimal outcomes. In conclusion, the text advocates for a paradigm shift in staging systems prioritizing treatment suitability over cancer stage. This reflects the evolving landscape of HCC management, where a multidisciplinary approach is crucial for tailoring treatments to individual patients, ultimately aiming to improve overall survival.

Keyword

Carcinoma, hepatocellular; Intermediate stage, staging system

Reference

References

1. Union for International Cancer Control (UICC). UICC and the TNM classification of malignant tumours [Internet]. Geneva: UICC [cited 2024 Jan 16]. Available from: https://www.uicc.org/who-we-are/about-uicc/uiccand-tnm.

2. Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W. Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open. 2016; 1:e000042.

3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71:209–249.

4. Maucort-Boulch D, de Martel C, Franceschi S, Plummer M. Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide. Int J Cancer. 2018; 142:2471–2477.

5. Izumi R, Shimizu K, Ii T, Yagi M, Matsui O, Nonomura A, et al. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology. 1994; 106:720–727.

6. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334:693–699.

7. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985; 56:918–928.

8. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999; 19:329–338.

9. Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005; 41:707–716.

10. Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol. 2006; 44:723–731.

11. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003; 362:1907–1917.

12. Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022; 76:681–693.

13. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018; 391:1301–1314.

14. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010; 30:61–74.

15. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012; 379:1245–1255.

16. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018; 69:182–236.

17. Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023; 78:1922–1965.

18. Garuti F, Neri A, Avanzato F, Gramenzi A, Rampoldi D, Rucci P, et al. The changing scenario of hepatocellular carcinoma in Italy: an update. Liver Int. 2021; 41:585–597.

19. Reggidori N, Bucci L, Santi V, Stefanini B, Lani L, Rampoldi D, et al. Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs. JHEP Rep. 2023; 5:100784.

20. Bolondi L, Burroughs A, Dufour JF, Galle PR, Mazzaferro V, Piscaglia F, et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 2012; 32:348–359.

21. Weinmann A, Koch S, Sprinzl M, Kloeckner R, Schulze-Bergkamen H, Düber C, et al. Survival analysis of proposed BCLC-B subgroups in hepatocellular carcinoma patients. Liver Int. 2015; 35:591–600.

22. Giannini EG, Moscatelli A, Pellegatta G, Vitale A, Farinati F, Ciccarese F, et al. Application of the intermediate-stage subclassification to patients with untreated hepatocellular carcinoma. Am J Gastroenterol. 2016; 111:70–77.

23. Ha Y, Shim JH, Kim SO, Kim KM, Lim YS, Lee HC. Clinical appraisal of the recently proposed Barcelona Clinic Liver Cancer stage B subclassification by survival analysis. J Gastroenterol Hepatol. 2014; 29:787–793.

24. Wang JH, Kee KM, Lin CY, Hung CH, Chen CH, Lee CM, et al. Validation and modification of a proposed substaging system for patients with intermediate hepatocellular carcinoma. J Gastroenterol Hepatol. 2015; 30:358–363.

25. Kudo M, Arizumi T, Ueshima K, Sakurai T, Kitano M, Nishida N. Subclassification of BCLC B stage hepatocellular carcinoma and treatment strategies: proposal of modified Bolondi's subclassification (Kinki criteria). Dig Dis. 2015; 33:751–758.

26. Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, et al. Validation of a modified substaging system (Kinki criteria) for patients with intermediate-stage hepatocellular carcinoma. Oncology. 2015; 89 Suppl 2:47–52.

27. Yamamoto M, Kobayashi T, Hashimoto M, Kuroda S, Kawaoka T, Aikata H, et al. Significance of liver resection for intermediate stage hepatocellular carcinoma according to subclassification. BMC Cancer. 2021; 21:668.

28. Yamakado K, Miyayama S, Hirota S, Mizunuma K, Nakamura K, Inaba Y, et al. Subgrouping of intermediate-stage (BCLC stage B) hepatocellular carcinoma based on tumor number and size and Child-Pugh grade correlated with prognosis after transarterial chemoembolization. Jpn J Radiol. 2014; 32:260–265.

29. Lee S, Kim BK, Song K, Park JY, Ahn SH, Kim SU, et al. Subclassification of Barcelona Clinic Liver Cancer B and C hepatocellular carcinoma: a cohort study of the multicenter registry database. J Gastroenterol Hepatol. 2016; 31:842–847.

30. Kim JH, Shim JH, Lee HC, Sung KB, Ko HK, Ko GY, et al. New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization. Liver Int. 2017; 37:1861–1868.

31. Kimura H, Ohkawa K, Miyazaki M, Sakakibara M, Imanaka K, Tamura T, et al. Subclassification of patients with intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinoma using the up-toseven criteria and serum tumor markers. Hepatol Int. 2017; 11:105–114.

32. Ielasi L, Stefanini B, Conti F, Tonnini M, Tortora R, Magini G, et al. Comparative analysis of subclassification systems in patients with intermediate-stage hepatocellular carcinoma (Barcelona Clinic Liver Classification B) receiving systemic therapy. Curr Oncol. 2024; 31:547–557.

33. Cook JA, Ranstam J. Overfitting. Br J Surg. 2016; 103:1814.

34. Kikuchi L, Chagas AL, Alencar RSSM, Tani C, Diniz MA, D'Albuquerque LAC, et al. Adherence to BCLC recommendations for the treatment of hepatocellular carcinoma: impact on survival according to stage. Clinics (Sao Paulo). 2017; 72:454–460.

35. Richani M, Kolly P, Knoepfli M, Herrmann E, Zweifel M, von TenggKobligk H, et al. Treatment allocation in hepatocellular carcinoma: assessment of the BCLC algorithm. Ann Hepatol. 2016; 15:82–90.

36. Galle PR, Tovoli F, Foerster F, Wörns MA, Cucchetti A, Bolondi L. The treatment of intermediate stage tumours beyond TACE: from surgery to systemic therapy. J Hepatol. 2017; 67:173–183.

37. Yin L, Li H, Li AJ, Lau WY, Pan ZY, Lai EC, et al. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan criteria: a RCT. J Hepatol. 2014; 61:82–88.

38. Pecorelli A, Lenzi B, Gramenzi A, Garuti F, Farinati F, Giannini EG, et al. Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma. Liver Int. 2017; 37:423–433.

39. Tada T, Kumada T, Toyoda H, Tsuji K, Hiraoka A, Itobayashi E, et al. Role of hepatic resection in patients with intermediate-stage hepatocellular carcinoma: a multicenter study from Japan. Cancer Sci. 2017; 108:1414–1420.

40. Jianyong L, Lunan Y, Wentao W, Yong Z, Bo L, Tianfu W, et al. Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma: transarterial chemoembolization or hepatic resection? Medicine (Baltimore). 2014; 93:e180.

41. Lin CL, Lin CK, Lin TJ, Lee HC, Chen KY, Liao LY, et al. Comparison of surgical resection and transarterial chemoembolization for patients with intermediate stage hepatocellular carcinoma. J Cancer Res Pract. 2016; 3:34–38.

42. Zhao YN, Zhang YQ, Ye JZ, Liu X, Yang HZ, Cong FY, et al. Hepatic resection versus transarterial chemoembolization for patients with Barcelona Clinic Liver Cancer intermediate stage Child-Pugh A hepatocellular carcinoma. Exp Ther Med. 2016; 12:3813–3819.

43. Lin CT, Hsu KF, Chen TW, Yu JC, Chan DC, Yu CY, et al. Comparing hepatic resection and transarterial chemoembolization for Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma: change for treatment of choice? World J Surg. 2010; 34:2155–2161.

44. Ciria R, López-Cillero P, Gallardo AB, Cabrera J, Pleguezuelo M, Ayllón MD, et al. Optimizing the management of patients with BCLC stageB hepatocellular carcinoma: modern surgical resection as a feasible alternative to transarterial chemoemolization. Eur J Surg Oncol. 2015; 41:1153–1161.

45. Luo J, Peng ZW, Guo RP, Zhang YQ, Li JQ, Chen MS, et al. Hepatic resection versus transarterial lipiodol chemoembolization as the initial treatment for large, multiple, and resectable hepatocellular carcinomas: a prospective nonrandomized analysis. Radiology. 2011; 259:286–295.

46. Kamo N, Kaido T, Yagi S, Okajima H, Uemoto S. Liver transplantation for intermediate-stage hepatocellular carcinoma. Liver Cancer. 2018; 7:179–189.

47. Tsai MC, Yong CC, Lin CC, Lee WC, Wang CC, Hung CH, et al. Living donor liver transplantation for Barcelona Clinic Liver Cancer (BCLC) intermediate-stage hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2023; 12:169–182.

48. D'Avola D, Iñarrairaegui M, Pardo F, Rotellar F, Marti P, Bilbao JI, et al. Prognosis of hepatocellular carcinoma in relation to treatment across BCLC stages. Ann Surg Oncol. 2011; 18:1964–1971.

49. Ho EY, Cozen ML, Shen H, Lerrigo R, Trimble E, Ryan JC, et al. Expanded use of aggressive therapies improves survival in early and intermediate hepatocellular carcinoma. HPB (Oxford). 2014; 16:758–767.

50. Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology. 2016; 64:106–116.

51. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003; 37:429–442.

52. Salem R, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, et al. Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2016; 151:1155–1163.e2.

53. Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the LEGACY study. Hepatology. 2021; 74:2342–2352.

54. Guiu B, Garin E, Allimant C, Edeline J, Salem R. TARE in hepatocellular carcinoma: from the right to the left of BCLC. Cardiovasc Intervent Radiol. 2022; 45:1599–1607.

55. Stefanini B, Ielasi L, Chen R, Abbati C, Tonnini M, Tovoli F, et al. TKIs in combination with immunotherapy for hepatocellular carcinoma. Expert Rev Anticancer Ther. 2023; 23:279–291.

56. Foerster F, Kloeckner R, Reig M, Chan SL, Chung JW, Merle P, et al. ABC-HCC: a phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma. J Clin Oncol. 2022; 40 Suppl 4:TPS498.

57. Lencioni R, Kudo M, Erinjeri J, Qin S, Ren Z, Chan S, et al. EMERALD-1: a phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization. J Clin Oncol. 2024; 42 Suppl 3:LBA432.

58. Golfieri R, Cappelli A, Cucchetti A, Piscaglia F, Carpenzano M, Peri E, et al. Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas. Hepatology. 2011; 53:1580–1589.

59. Topalian SL, Forde PM, Emens LA, Yarchoan M, Smith KN, Pardoll DM. Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy. Cancer Cell. 2023; 41:1551–1566.

60. Vitale A, Farinati F, Pawlik TM, Frigo AC, Giannini EG, Napoli L, et al. The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: a multicenter cohort study. Liver Int. 2019; 39:1478–1489.

61. Serper M, Taddei TH, Mehta R, D'Addeo K, Dai F, Aytaman A, et al. Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality. Gastroenterology. 2017; 152:1954–1964.

62. Vitale A, Trevisani F, Farinati F, Cillo U. Treatment of hepatocellular carcinoma in the precision medicine era: from treatment stage migration to therapeutic hierarchy. Hepatology. 2020; 72:2206–2218.

63. Vitale A, Cabibbo G, Iavarone M, Viganò L, Pinato DJ, Ponziani FR, et al. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept. Lancet Oncol. 2023; 24:e312–e322.

64. Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer. 2021; 10:181–223.

65. Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017; 11:317–370.

66. Korean Liver Cancer Association; National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea practice guidelines for the management of hepatocellular carcinoma. Gut Liver. 2019; 13:227–299.

67. Lu J, Zhang XP, Zhong BY, Lau WY, Madoff DC, Davidson JC, et al. Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing East and West. Lancet Gastroenterol Hepatol. 2019; 4:721–730.

68. D'Avola D, Granito A, Torre-Aláez M, Piscaglia F. The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma. J Hepatol. 2022; 76:1185–1198.

69. El Dahan KS, Reczek A, Daher D, Rich NE, Yang JD, Hsiehchen D, et al. Multidisciplinary care for patients with HCC: a systematic review and meta-analysis. Hepatol Commun. 2023; 7:e0143.

70. Reig M, Darnell A, Forner A, Rimola J, Ayuso C, Bruix J. Systemic therapy for hepatocellular carcinoma: the issue of treatment stage migration and registration of progression using the BCLC-refined RECIST. Semin Liver Dis. 2014; 34:444–455.